debt_leverage_profile
0.00x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low-moderate; ~$200M convertible notes at fixed rates, 20bps rate shift has minimal P&L impact but affects refinancing cost marginally
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Taiwan/South Korea semiconductor supply for sequencing instruments; single-source reagent suppliers concentrated in Western Europe
Inferred
Agent_Inference
international_expansion_readiness
Limited international revenue (~10-15% of total); EUR exposure primary, with CHF and GBP secondary; hedging minimal
Inferred
Agent_Inference
geographic_footprint
~85% US revenue; EUR is largest FX risk, modest CHF/GBP exposure; no material emerging-market currency devaluation risk currently
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Illumina represents non-substitutable sequencing platform dependency exceeding 30% of lab input costs; high lock-in risk
Inferred
Agent_Inference
business_model_type_primary
Cloud disruption would impair bioinformatics pipeline and genomic data analysis; 30-day migration feasible but costly, ~3-6 months full recovery
Inferred
Agent_Inference
business_model_type_secondary
Diagnostics-as-a-service with fee-per-test revenue; cloud loss disrupts reporting workflows but lab instrumentation remains operational
Inferred
Agent_Inference
switching_cost_profile
High API coupling to Illumina BaseSpace and proprietary genomic classifiers; switching cost estimated 18-24 months redevelopment
Inferred
Agent_Inference
howey_test_risk_index
Fails Howey Test; diagnostic testing revenue is service-based, not an investment contract; near-zero securities classification risk
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
High HIPAA exposure; GDPR risk moderate for EU genomic data; CCPA applicable; genomic data classified as sensitive requiring elevated compliance spend
Inferred
Agent_Inference
antitrust_exposure_flag
Low-moderate; niche genomic diagnostics market; Decipher/Prosigna portfolio creates bundling risk but market share insufficient for DOJ scrutiny
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~70% transactional (per-test reimbursement), ~30% recurring (biopharma partnerships, multi-year contracts); predominantly fee-for-service
Inferred
Agent_Inference
monetization_vector
Per-test reimbursement from Medicare/Medicaid and commercial payers; supplemented by biopharma research partnerships and licensing
Inferred
Agent_Inference
pricing_architecture
Reimbursement-dependent pricing (~$3,000-$5,000 per test); Medicare LCD coverage drives volume; payer mix compression is primary pricing risk
Inferred
Agent_Inference
pricing_power_rating
Moderate; pricing constrained by CMS reimbursement schedules; clinical utility data supports premium but payer pushback limits upside; 6/10
Inferred
Agent_Inference
target_gross_margin_bracket
70.1% Gross Margin (Premium (>60%))
High
SEC-XBRL
churn_vulnerability_index
No free-rider problem; ordered tests require physician prescription; churn risk is physician adoption attrition, estimated 15-20% annually per new ordering physician
Inferred
Agent_Inference
headcount_cost_structure
Sublinear growth possible; lab automation and AI-driven genomic analysis reduce per-test labor; doubling revenue requires ~40-50% headcount increase
Inferred
Agent_Inference
marginal_cost_of_growth
Favorable marginal economics; incremental test costs ~$300-500 in COGS vs $3,000+ revenue; gross margin expansion expected as volume scales
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company operates company-owned CAP/CLIA certified labs, no franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely declines via key opinion leader leverage; LTV/CAC ratio currently ~4-6x, improving with specialty penetration
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; data flywheel exists—larger genomic dataset improves classifier accuracy, creating indirect competitive moat
Inferred
Agent_Inference
asset_efficiency_ratio
4.9% Return on Assets (Excellent)
High
SEC-XBRL
recession_resistance_tier
Tier 2 resilient; cancer diagnostics are medically necessary, but elective biopsy deferral in recessions reduces test volumes 10-20%
Inferred
Agent_Inference
customer_segment_primary
Urologists, oncologists, and pathologists ordering genomic tests; no single physician/institution exceeds 5% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Biopharma companies (AstraZeneca, J&J) as research partners; payer concentration risk with Medicare representing ~40% of reimbursements
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
1.9% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0001384101
High
SEC-EDGAR
ticker
VCYT
High
SEC-EDGAR